Phentermine-Topiramate (Qsymia) for Weight Loss: Evidence, Safety, and How It Compares in 2026

The short version

Phentermine-topiramate (brand name Qsymia) is an oral, once-daily combination pill approved by the FDA in 2012 for chronic weight management. In the phase 3 trials, adults on the top dose lost roughly 9 to 10 percent of body weight over 56 weeks, and that loss held for two years in an extension study. [1][4] It works by pairing an appetite-suppressing stimulant with a drug that increases fullness. It is cheaper than GLP-1 injections and taken by mouth, but it carries real cautions: topiramate can harm a fetus, so it is contraindicated in pregnancy and dispensed under a risk program, and its stimulant half raises heart rate. [2] For many people GLP-1 drugs produce more weight loss, so the choice comes down to cost, tolerance, and personal risk factors.

What it is and how it works

Qsymia combines two older drugs at low doses. Phentermine is a sympathomimetic amine, a stimulant related to amphetamine that triggers norepinephrine release in the brain and blunts appetite. It has been used short-term for weight loss since the 1950s. Topiramate is an anticonvulsant that is FDA-approved on its own for epilepsy and for migraine prevention, not for weight. [5] Its effect on eating is less fully mapped, but it appears to increase satiety and reduce food intake, likely through GABA modulation, carbonic anhydrase inhibition, and changes in taste.

Combining them at low doses lets each drug do part of the work while keeping the dose of each below the level where side effects usually pile up. Treatment starts at 3.75 mg phentermine / 23 mg topiramate for 14 days, then steps up to the standard 7.5/46 dose. If a person has not lost at least 3 percent of body weight after 12 weeks, the dose can be titrated to a maximum of 15/92. If the top dose does not produce meaningful loss, the label directs stopping, and topiramate should be tapered rather than stopped abruptly. [2]

What the trials actually show

The pivotal evidence comes from three phase 3 trials. CONQUER, a 56-week trial in overweight and obese adults with weight-related conditions, found that the top 15/92 dose produced about 9.8 percent mean weight loss versus roughly 1.2 percent on placebo. Seventy percent of top-dose patients lost at least 5 percent of body weight, and 48 percent lost at least 10 percent, against 21 percent and 7 percent on placebo. [1] EQUIP studied adults with more severe obesity (BMI 35 or higher) and reported around 11 percent weight loss at the top dose over the same period. [3]

Durability matters, because weight tends to return when treatment stops. SEQUEL followed CONQUER completers for a second year. At 108 weeks, top-dose patients maintained about 9.3 percent weight loss versus 1.8 percent on placebo, along with improvements in blood pressure, triglycerides, and fasting glucose. [4] In plain terms: the drug works while you take it, the effect is real and sustained on therapy, and it is dose-dependent.

Topiramate alone: off-label use and where the evidence stands

Topiramate by itself is prescribed off-label for weight, and it does produce dose-dependent weight loss in studies of people taking it for epilepsy and migraine. But it is not FDA-approved for weight management as a single drug, and the controlled weight-loss evidence sits with the combination product, not monotherapy. [5] The approved, studied path is the fixed phentermine-topiramate combination.

This is a genuine distinction, not a technicality. Off-label topiramate skips the dosing structure, monitoring, and pregnancy safeguards built into the approved product, while carrying the same central nervous system and teratogenicity risks. Whether topiramate makes sense for a given person, alone or in combination, is a clinical decision, not a self-directed one.

How it compares to GLP-1 drugs

On raw weight loss, GLP-1 medications generally win. Semaglutide 2.4 mg (Wegovy) produced about 14.9 percent mean weight loss in its pivotal trial, and tirzepatide (Zepbound) reached roughly 15 to 21 percent depending on dose. [6][7] Phentermine-topiramate's 9 to 10 percent is meaningful and clinically useful, but usually lower.

The trade-offs run the other way on cost and format. Qsymia is an oral pill and, as an older generic-component drug, is far less expensive out of pocket than branded GLP-1 injections, which can run many hundreds of dollars a month without coverage. For someone who cannot afford a GLP-1, will not inject, or does not tolerate GLP-1 gastrointestinal side effects, phentermine-topiramate is a reasonable, evidence-backed alternative. The decision is less about which drug is strongest and more about which risk-cost-tolerance profile fits the person.

Safety: the cautions that matter

The single most important caution is pregnancy. Topiramate taken in the first trimester raises the risk of oral clefts (cleft lip and palate) and small-for-gestational-age babies, so Qsymia is contraindicated in pregnancy. People who can become pregnant need a negative pregnancy test before starting and monthly during treatment, and effective contraception. Because of this, the drug is dispensed under an FDA Risk Evaluation and Mitigation Strategy (REMS). [2]

Other documented effects include increased heart rate from the phentermine component, tingling in the hands and feet (paresthesia), altered taste, trouble concentrating or word-finding, and mood changes including depression and, rarely, suicidal thoughts. Topiramate can also cause metabolic acidosis, kidney stones, and a rare but urgent acute myopia with angle-closure glaucoma that needs immediate care. [2] Qsymia is contraindicated in glaucoma and hyperthyroidism, and it must not be used with or within 14 days of MAO inhibitors.

Who it suits and who should avoid it

Phentermine-topiramate is approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, or high cholesterol, alongside reduced-calorie diet and increased activity. It suits people who want an oral option, are cost-sensitive, and do not have the specific risk factors the label rules out.

It is a poor fit for anyone who is pregnant or planning pregnancy, has glaucoma or hyperthyroidism, has a history of significant cardiovascular disease given the stimulant effect on heart rate, or has had adverse reactions to sympathomimetics. Because phentermine is a controlled substance and topiramate has cognitive effects, clinicians weigh history of substance use, mood disorders, and kidney stones before prescribing.

Cost, access, and the practical bottom line

Qsymia is a Schedule IV controlled substance because of the phentermine component, which means it requires a prescription and, in many states, added dispensing controls. It is available through pharmacies and via telehealth platforms that handle the REMS pregnancy-testing requirements. Cash prices are typically a fraction of branded GLP-1 costs, and manufacturer savings programs exist, though coverage for anti-obesity drugs varies widely by plan.

The practical read: phentermine-topiramate is an older, oral, lower-cost tool that reliably delivers high-single-digit to low-double-digit weight loss when taken consistently. It is not as powerful as the newest GLP-1 injections, and its topiramate half brings pregnancy and central nervous system cautions that a GLP-1 does not. For the right person, screened for the contraindications and monitored, it is a legitimate evidence-based choice rather than a second-rate one.